US Patent

US11827642 — Compositions useful for treating disorders related to KIT

Method of Use · Assigned to Blueprint Medicines Corp · Expires 2034-10-15 · 8y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions useful for treating disorders related to mutant KIT.

USPTO Abstract

Compounds and compositions useful for treating disorders related to mutant KIT are described herein.

Drugs covered by this patent

Ayvakit (AVAPRITINIB) · Blueprint Medicines

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3506`	—	Ayvakit

Patent Metadata

Patent number: US11827642
Jurisdiction: US
Classification: Method of Use
Expires: 2034-10-15
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Blueprint Medicines Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.